SG11201906264YA - Improved serum albumin binders - Google Patents
Improved serum albumin bindersInfo
- Publication number
- SG11201906264YA SG11201906264YA SG11201906264YA SG11201906264YA SG11201906264YA SG 11201906264Y A SG11201906264Y A SG 11201906264YA SG 11201906264Y A SG11201906264Y A SG 11201906264YA SG 11201906264Y A SG11201906264Y A SG 11201906264YA SG 11201906264Y A SG11201906264Y A SG 11201906264YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- serum albumin
- pct
- variable domains
- single variable
- Prior art date
Links
- 102000007562 Serum Albumin Human genes 0.000 title abstract 5
- 108010071390 Serum Albumin Proteins 0.000 title abstract 5
- 239000011230 binding agent Substances 0.000 title abstract 2
- 108060003951 Immunoglobulin Proteins 0.000 abstract 3
- 102000018358 immunoglobulin Human genes 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762446988P | 2017-01-17 | 2017-01-17 | |
| PCT/EP2018/051083 WO2018134235A1 (en) | 2017-01-17 | 2018-01-17 | Improved serum albumin binders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201906264YA true SG11201906264YA (en) | 2019-08-27 |
Family
ID=61521465
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201906264YA SG11201906264YA (en) | 2017-01-17 | 2018-01-17 | Improved serum albumin binders |
| SG10202108972RA SG10202108972RA (en) | 2017-01-17 | 2018-01-17 | Improved serum albumin binders |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202108972RA SG10202108972RA (en) | 2017-01-17 | 2018-01-17 | Improved serum albumin binders |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11414481B2 (enExample) |
| EP (3) | EP3571225B1 (enExample) |
| JP (3) | JP7219220B2 (enExample) |
| KR (2) | KR102662499B1 (enExample) |
| CN (2) | CN117285623A (enExample) |
| AU (2) | AU2018209151B2 (enExample) |
| BR (1) | BR112019014599A2 (enExample) |
| CA (1) | CA3050575A1 (enExample) |
| DK (1) | DK3571225T3 (enExample) |
| ES (1) | ES2991459T3 (enExample) |
| FI (1) | FI3571225T3 (enExample) |
| HR (1) | HRP20241469T1 (enExample) |
| HU (1) | HUE068790T2 (enExample) |
| IL (2) | IL267894B2 (enExample) |
| LT (1) | LT3571225T (enExample) |
| MX (2) | MX2019008496A (enExample) |
| PT (1) | PT3571225T (enExample) |
| RS (1) | RS66117B1 (enExample) |
| SG (2) | SG11201906264YA (enExample) |
| SI (1) | SI3571225T1 (enExample) |
| WO (1) | WO2018134235A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11644471B2 (en) | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| AU2012273929B2 (en) * | 2011-06-23 | 2017-04-27 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| AU2017373746B2 (en) | 2016-12-07 | 2024-11-14 | Ablynx Nv | Improved serum albumin binding immunoglobulin single variable domains |
| MX2019008496A (es) * | 2017-01-17 | 2019-09-18 | Ablynx Nv | Aglutinantes de albumina serica mejorados. |
| KR20230165374A (ko) * | 2017-01-17 | 2023-12-05 | 아블린쓰 엔.브이. | 개선된 혈청 알부민 결합제 |
| MX2022006881A (es) | 2019-12-06 | 2022-07-11 | Ablynx Nv | Polipeptidos que comprenden dominios variables unicos de inmunoglobulina dirigidos a tnf alfa y ox40l. |
| WO2021110816A1 (en) | 2019-12-06 | 2021-06-10 | Ablynx Nv | POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TNFα AND IL-23 |
| TW202530257A (zh) | 2019-12-09 | 2025-08-01 | 比利時商艾伯霖克斯公司 | 包含靶向il-13及tslp之免疫球蛋白單可變域的多肽 |
| WO2021140205A1 (en) | 2020-01-10 | 2021-07-15 | Confo Therapeutics N.V. | Methods for generating antibodies and antibody fragments and libraries comprising same |
| CA3175873A1 (en) | 2020-03-30 | 2021-10-07 | Ablynx Nv | Method for the production and purification of multivalent immunoglobulin single variable domains |
| WO2022063984A1 (en) | 2020-09-25 | 2022-03-31 | Ablynx Nv | Polypeptides comprising immunoglobulin single variable domains targeting il-13 and ox40l |
| KR20230122084A (ko) | 2020-12-18 | 2023-08-22 | 아블린쓰 엔.브이. | Tcr 알파/베타 반응성에 기초한 t 세포 동원 폴리펩타이드 |
| TW202241947A (zh) | 2020-12-18 | 2022-11-01 | 比利時商艾伯霖克斯公司 | 包含靶向磷脂醯肌醇蛋白聚糖—３和ｔ細胞受體的免疫球蛋白單可變結構域的多肽 |
| WO2022129572A1 (en) | 2020-12-18 | 2022-06-23 | Ablynx Nv | Polypeptides comprising immunoglobulin single variable domains targeting il-6 and tnf-alpha |
| AU2022409733A1 (en) | 2021-12-17 | 2024-08-01 | Ablynx Nv | POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TCRαβ, CD33 AND CD123 |
| KR20250023503A (ko) | 2022-06-14 | 2025-02-18 | 아블린쓰 | T 세포 수용체를 표적화하는 면역글로불린 단일 가변 도메인 |
| KR20250042176A (ko) | 2022-07-27 | 2025-03-26 | 아블린쓰 | 신생아 fc 수용체의 특정 에피토프에 결합하는 폴리펩타이드 |
| WO2024084203A1 (en) | 2022-10-18 | 2024-04-25 | Isogenica Limited | Single domain antibodies binding to albumin |
| WO2024133935A1 (en) | 2022-12-23 | 2024-06-27 | Ablynx Nv | Protein-based conjugation carriers |
| WO2024151515A2 (en) | 2023-01-09 | 2024-07-18 | Odyssey Therapeutics, Inc. | Anti-tnfr2 antigen-binding proteins and uses thereof |
| CN120712282A (zh) | 2023-02-17 | 2025-09-26 | 阿布林克斯有限公司 | 结合新生儿fc受体的多肽 |
| AU2024234615A1 (en) | 2023-03-14 | 2025-08-21 | Odyssey Therapeutics, Inc. | Anti-cd25 antigen-binding proteins and uses thereof |
| WO2024238790A1 (en) | 2023-05-17 | 2024-11-21 | Odyssey Therapeutics, Inc. | Modified single-domain antibodies |
| KR102822958B1 (ko) * | 2023-05-23 | 2025-06-20 | 대한민국(해양경찰청 해양경찰연구센터장) | 고래 불법포획 감식용 신속진단키트 |
| WO2024261235A1 (en) | 2023-06-22 | 2024-12-26 | Ablynx Nv | Chimeric proteins for modulating cytokine receptor activity |
| AU2024308381A1 (en) | 2023-06-29 | 2025-11-20 | Odyssey Therapeutics, Inc. | Anti-trailr2 antigen-binding proteins and uses thereof |
| US20250034260A1 (en) | 2023-07-05 | 2025-01-30 | Sanofi | Fcrn antagonists for treatment of igg-related diseases and disorders |
| WO2025051767A1 (en) | 2023-09-04 | 2025-03-13 | Sanofi | Polypeptides for use in the treatment of glypican-3-expressing tumours |
| TW202532432A (zh) | 2023-09-22 | 2025-08-16 | 比利時商艾伯霖克斯公司 | 二及多價白蛋白結合劑 |
| TW202530265A (zh) | 2023-10-13 | 2025-08-01 | 美商奧迪希治療公司 | 抗cdh17抗原結合蛋白及其用途 |
| WO2025099632A1 (en) | 2023-11-08 | 2025-05-15 | Sanofi | Cd25 based lysosomal degrader and uses thereof |
| US20250296991A1 (en) | 2023-12-01 | 2025-09-25 | Ablynx N.V. | Precision activated polypeptides |
| WO2025133253A2 (en) | 2023-12-22 | 2025-06-26 | Ablynx Nv | Protein-based conjugation carriers for intranuclear delivery |
| US20250236673A1 (en) | 2023-12-22 | 2025-07-24 | Ablynx N.V. | Protein-based carriers for site-specific amine conjugation |
| WO2025217240A1 (en) | 2024-04-10 | 2025-10-16 | Odyssey Therapeutics, Inc. | Anti-tnfr2 antigen-binding proteins and uses thereof |
| WO2025217579A1 (en) * | 2024-04-12 | 2025-10-16 | Paragon Therapeutics, Inc. | Anti-hsa vhh antibodies and compositions thereof |
| US12459994B2 (en) | 2024-04-12 | 2025-11-04 | Paragon Therapeutics, Inc. | Albumin binding proteins and methods of use |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| EP1027439B1 (en) | 1997-10-27 | 2010-03-17 | Bac Ip B.V. | Multivalent antigen-binding proteins |
| US6742038B2 (en) | 2000-04-07 | 2004-05-25 | Danger, Inc. | System and method of linking user identification to a subscriber identification module |
| JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
| CA2492092A1 (en) | 2002-06-28 | 2004-01-08 | Greg Winter | Immunoglobin single variant antigen-binding domains and dual-specific constructs |
| US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| US20060002935A1 (en) | 2002-06-28 | 2006-01-05 | Domantis Limited | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
| CA2505325C (en) | 2002-11-08 | 2014-02-25 | Ablynx N.V. | Stabilized single domain antibodies |
| KR20080113286A (ko) | 2003-01-10 | 2008-12-29 | 아블린쓰 엔.브이. | 폰 빌레브란트 인자(ｖＷＦ) 또는 콜라겐에 대한 낙타과로부터의 재조합 ＶＨＨ 단일 도메인 항체 |
| CA2588892A1 (en) | 2004-12-02 | 2006-06-08 | Dormantis Limited | Anti-il-1r1 single domain antibodies and therapeutic uses |
| BR122013001996B1 (pt) | 2005-05-18 | 2022-02-01 | Ablynx N.V. | Nanocorpos melhorados contra fator alfa de necrose tumoral |
| CN101213214B (zh) | 2005-05-20 | 2014-06-25 | 埃博灵克斯股份有限公司 | 针对冯威勒布兰特因子的单一结构域vhh抗体 |
| EA200801170A1 (ru) | 2005-12-01 | 2008-12-30 | Домантис Лимитед | Форматы неконкурентного доменного антитела, которые связываются с рецептором интерлейкина 1 первого типа |
| KR20080077237A (ko) | 2005-12-01 | 2008-08-21 | 도만티스 리미티드 | 인터루킨 1 수용체 타입 1에 결합하는 경쟁적 도메인 항체포맷 |
| FR2894741B1 (fr) | 2005-12-08 | 2009-12-04 | Centre Nat Etd Spatiales | Chaine de reception par satellite |
| CA2640066A1 (en) | 2006-01-24 | 2007-08-02 | Roland Beckmann | Fusion proteins that contain natural junctions |
| CA2666599A1 (en) | 2006-08-18 | 2008-02-21 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling |
| CN101646689A (zh) * | 2006-09-08 | 2010-02-10 | 埃博灵克斯股份有限公司 | 具有长半衰期的血清清蛋白结合蛋白 |
| RU2481355C2 (ru) | 2007-05-24 | 2013-05-10 | Аблинкс Н.В. | Аминокислотные последовательности, направленные на rank-l, и полипептиды, включающие их, для лечения заболеваний и нарушений костей |
| WO2009068631A1 (en) | 2007-11-27 | 2009-06-04 | Ablynx N.V. | Method for obtaining polypeptide constructs comprising two or more single domain antibodies |
| DE102008023620A1 (de) | 2008-05-15 | 2009-11-19 | Mettler-Toledo (Albstadt) Gmbh | Funktionseinheit mit einer aufrufbaren Funktion und Verfahren zu deren Aufruf |
| US9212226B2 (en) | 2008-05-16 | 2015-12-15 | Ablynx N.V. | Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same |
| WO2010035012A1 (en) | 2008-09-26 | 2010-04-01 | Ucb Pharma S.A. | Biological products |
| WO2010130832A2 (en) | 2009-05-15 | 2010-11-18 | Ablynx N.V. | Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions |
| CN102574914A (zh) | 2009-07-16 | 2012-07-11 | 葛兰素集团有限公司 | 改进的抗血清清蛋白结合性单可变区 |
| MX2012003939A (es) | 2009-09-30 | 2012-07-30 | Glaxo Group Ltd | Fusiones y conjugados de farmaco. |
| JP2013538566A (ja) | 2010-08-13 | 2013-10-17 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | 改良された抗血清アルブミン結合変異体 |
| BR112013003899A2 (pt) | 2010-08-20 | 2016-06-07 | Glaxosmithkline Ip Dev Ltd | domínio variável único da imunoglobina anti-albumina sérica (sa), ligando multiespecífico, proteína de fusão, composição, ácido nucleico, vetor, célula hospedeira isolada, e, método de tratar ou previnir uma doença ou distúrbio em um paciente |
| US11644471B2 (en) * | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| CN106046168A (zh) | 2011-06-23 | 2016-10-26 | 埃博灵克斯股份有限公司 | 结合血清白蛋白的蛋白 |
| US20150344568A1 (en) * | 2011-06-23 | 2015-12-03 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| AU2012273929B2 (en) | 2011-06-23 | 2017-04-27 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| EP3020728A1 (en) * | 2011-06-23 | 2016-05-18 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains |
| WO2012174741A1 (en) | 2011-06-24 | 2012-12-27 | Google Inc. | Determining cross-language query suggestion based on query translations |
| EA027160B1 (ru) | 2011-08-17 | 2017-06-30 | Глаксо Груп Лимитед | Модифицированные белки и пептиды |
| US20130129727A1 (en) * | 2011-11-17 | 2013-05-23 | Nanjingjinsirui Science & Technology Biology Corporation | Methods and systems for increasing protein stability |
| WO2014037419A1 (en) | 2012-09-04 | 2014-03-13 | Vib Vzw | Immunoglobulin single variable domains directed against cd74 and uses derived thereof |
| US20140186365A1 (en) * | 2013-01-03 | 2014-07-03 | Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center | Antibodies that specifically bind to serum albumin without interfering with albumin's capability to interact with the fcrn |
| WO2014111550A1 (en) | 2013-01-17 | 2014-07-24 | Glaxosmithkline Intellectual Property Development Limited | Modified anti-serum albumin binding proteins |
| CN106661100A (zh) | 2014-05-16 | 2017-05-10 | 埃博灵克斯股份有限公司 | 改进的免疫球蛋白可变结构域 |
| CN107531777A (zh) | 2015-01-21 | 2018-01-02 | 英伊布里克斯有限合伙公司 | 非免疫原性单结构域抗体 |
| PL3294768T3 (pl) | 2015-05-13 | 2020-03-31 | Ablynx N.V. | Polipeptydy rekrutujące komórki T oparte na reaktywności TCR alfa/beta |
| HRP20220080T1 (hr) * | 2015-11-13 | 2022-04-15 | Ablynx N.V. | Poboljšane imunoglobulinske varijabilne domene koje vežu serumski albumin |
| TN2018000180A1 (en) | 2015-11-27 | 2019-10-04 | Ablynx Nv | Polypeptides inhibiting cd40l |
| AU2017373746B2 (en) | 2016-12-07 | 2024-11-14 | Ablynx Nv | Improved serum albumin binding immunoglobulin single variable domains |
| KR20230165374A (ko) * | 2017-01-17 | 2023-12-05 | 아블린쓰 엔.브이. | 개선된 혈청 알부민 결합제 |
| MX2019008496A (es) | 2017-01-17 | 2019-09-18 | Ablynx Nv | Aglutinantes de albumina serica mejorados. |
| TW202532432A (zh) * | 2023-09-22 | 2025-08-16 | 比利時商艾伯霖克斯公司 | 二及多價白蛋白結合劑 |
-
2018
- 2018-01-17 MX MX2019008496A patent/MX2019008496A/es unknown
- 2018-01-17 KR KR1020197024113A patent/KR102662499B1/ko active Active
- 2018-01-17 SG SG11201906264YA patent/SG11201906264YA/en unknown
- 2018-01-17 SI SI201831169T patent/SI3571225T1/sl unknown
- 2018-01-17 DK DK18707848.0T patent/DK3571225T3/da active
- 2018-01-17 IL IL267894A patent/IL267894B2/en unknown
- 2018-01-17 US US16/477,918 patent/US11414481B2/en active Active
- 2018-01-17 RS RS20241215A patent/RS66117B1/sr unknown
- 2018-01-17 KR KR1020247002265A patent/KR20240013861A/ko not_active Ceased
- 2018-01-17 ES ES18707848T patent/ES2991459T3/es active Active
- 2018-01-17 CN CN202311123454.3A patent/CN117285623A/zh active Pending
- 2018-01-17 EP EP18707848.0A patent/EP3571225B1/en active Active
- 2018-01-17 FI FIEP18707848.0T patent/FI3571225T3/fi active
- 2018-01-17 LT LTEPPCT/EP2018/051083T patent/LT3571225T/lt unknown
- 2018-01-17 BR BR112019014599-0A patent/BR112019014599A2/pt unknown
- 2018-01-17 AU AU2018209151A patent/AU2018209151B2/en active Active
- 2018-01-17 EP EP24191388.8A patent/EP4442707A3/en active Pending
- 2018-01-17 EP EP24191393.8A patent/EP4442709A3/en active Pending
- 2018-01-17 WO PCT/EP2018/051083 patent/WO2018134235A1/en not_active Ceased
- 2018-01-17 SG SG10202108972RA patent/SG10202108972RA/en unknown
- 2018-01-17 JP JP2019538382A patent/JP7219220B2/ja active Active
- 2018-01-17 PT PT187078480T patent/PT3571225T/pt unknown
- 2018-01-17 IL IL312292A patent/IL312292A/en unknown
- 2018-01-17 HR HRP20241469TT patent/HRP20241469T1/hr unknown
- 2018-01-17 CA CA3050575A patent/CA3050575A1/en active Pending
- 2018-01-17 CN CN201880007313.6A patent/CN110191896B/zh active Active
- 2018-01-17 HU HUE18707848A patent/HUE068790T2/hu unknown
-
2019
- 2019-07-16 MX MX2023005374A patent/MX2023005374A/es unknown
-
2022
- 2022-06-29 US US17/852,604 patent/US20230060574A1/en active Pending
- 2022-12-08 JP JP2022196232A patent/JP7628996B2/ja active Active
-
2024
- 2024-11-22 JP JP2024204085A patent/JP2025026992A/ja active Pending
-
2025
- 2025-05-13 AU AU2025203430A patent/AU2025203430A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201906264YA (en) | Improved serum albumin binders | |
| SG11201906341XA (en) | Improved serum albumin binders | |
| SG11201906961UA (en) | Polypeptide variants and uses thereof | |
| SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
| SG11202000105QA (en) | Anti-cd166 antibodies and uses thereof | |
| SG11201903693QA (en) | Polypeptide variants and uses thereof | |
| SG11201909646TA (en) | Trem2 antigen binding proteins and uses thereof | |
| SG11201908540PA (en) | Stable antibody formulation | |
| SG11201907753TA (en) | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof | |
| SG11201901899PA (en) | Bispecific trivalent antibodies binding to claudin6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases | |
| SG11201804127SA (en) | Ctla4 binders | |
| SG11201907208XA (en) | Radiolabeled anti-lag3 antibodies for immuno-pet imaging | |
| SG11201804178YA (en) | Pd1 and/or lag3 binders | |
| SG11201803975SA (en) | Improved tnf binders | |
| SG11201906213UA (en) | Modulating expression of polypeptides via new gene switch expression systems | |
| SG11201809649WA (en) | Macromolecule analysis employing nucleic acid encoding | |
| SG11201903454VA (en) | Immunologically discernible cell surface variants for use in cell therapy | |
| SG11201811015RA (en) | Antibodies specific for hyperphosphorylated tau and methods of use thereof | |
| SG11201901528RA (en) | Proteolytically cleavable chimeric polypeptides and methods of use thereof | |
| SG11201910027YA (en) | Bispecific antibody against ox40 and ctla-4 | |
| SG11201900573UA (en) | Methods of purifying fc-containing proteins | |
| SG11201803958WA (en) | Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences | |
| SG11201810757YA (en) | Non-human animals expressing exogenous terminal deoxynucleotidyltransferase | |
| SG11201804857WA (en) | Anti-tl1a/anti-tnf-alpha bispecific antigen binding proteins and uses thereof | |
| SG11201908056QA (en) | Anti-par2 antibodies and uses thereof |